Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer
2009
Proposed Antiangiogenic Therapy for Early Stage Breast Cancer
publication
Evidence: low
Author Information
Author(s): Michael W Retsky, William J M Hrushesky, I D Gukas
Primary Institution: Children's Hospital and Harvard Medical School
Hypothesis
Can primary antiangiogenic therapy using Endostatin lead to improved outcomes in early stage breast cancer?
Conclusion
The proposed therapy using Endostatin may prevent micrometastatic angiogenesis and could eliminate the need for adjuvant chemotherapy or hormone therapy.
Supporting Evidence
- Women with Down syndrome rarely develop breast cancer, possibly due to higher levels of Endostatin.
- Endostatin is non-toxic and does not interfere with wound healing.
- Previous studies suggest that antiangiogenic therapy could prevent cancer progression.
Takeaway
This study suggests that giving a special protein called Endostatin before surgery can help stop cancer from spreading and might make other treatments unnecessary.
Limitations
The study relies on theoretical models and lacks direct clinical trial data to support the proposed therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website